BioPharmSignal logoBioPharmSignal

Biotech News

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Clearside Biomedical (CLSD)Clearside BiomedicalEarnings

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its first quarter

Related news

TARSTarsus Pharmaceuticals2026-04-29 20:30 EST

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

IRIXIRIDEX2026-05-05 20:05 EST

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

LCTXLineage Cell Therapeutics2026-05-05 12:00 EST

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

LENZLenz Therapeutics Inc2026-05-04 12:00 EST

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

EYPTEyePoint Pharmaceuticals2026-04-29 11:00 EST

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

OCULOcular Therapeutix2026-04-28 11:00 EST

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

HROWHarrow, Inc.2026-04-27 11:00 EST

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

SGHTSight Sciences2026-04-21 20:05 EST

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

BLTEBelite Bio2026-05-13 20:00 EST

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

OCGNOcugen2026-04-29 11:02 EST

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

View all latest news

Clearside Biomedical

Clearside Biomedical is a drug-delivery and ophthalmology company focused on delivering therapies directly to the back of the eye. Its platform is built around improving how eye treatments reach retinal tissue.

Recent company news

CLSDClearside Biomedical2025-11-24 12:05 EST

Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

CLSDClearside Biomedical2025-08-26 12:05 EST

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

CLSDClearside Biomedical2025-07-23 11:05 EST

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

CLSDClearside Biomedical2025-07-17 11:05 EST

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

CLSDClearside Biomedical2025-06-17 11:05 EST

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States